HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs

3Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

Abstract

Multiple myeloma (MM), a malignant plasma cell infiltration of the bone marrow, is generally considered incurable: resistance to multiple therapeutic drugs inevitably arises from tumor cell-intrinsic and tumor microenvironment (TME)-mediated mechanisms. Here we report that the proteoglycan tandem repeat 1 (PTR1) domain of the TME matrix protein, hyaluronan and proteoglycan link protein 1 (HAPLN1), induces a host of cell survival genes in MM cells and variable resistance to different classes of clinical drugs, including certain proteasome inhibitors, steroids, immunomodulatory drugs, and DNA damaging agents, in several MM cell lines tested. Collectively, our study identifies HAPLN1 as an extracellular matrix factor that can simultaneously confer MM cell resistance to multiple therapeutic drugs.

Cite

CITATION STYLE

APA

Huynh, M., Chang, H. Y., Lisiero, D. N., Ong, I. M., Kashyap, T., Callander, N. S., & Miyamoto, S. (2022). HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs. PLoS ONE, 17(12 December). https://doi.org/10.1371/journal.pone.0274704

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free